Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Atrium Therapeutics, Inc.NASDAQ: RNA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow of -$2.1M in Q1 FY2026
Q1 FY2026 investing cash flow was -$2.1M.
Context
- Investing cash flow amounted to 7.8% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (1.45M) USD
- Year-over-year change
- —
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.45M) | — |
Investing Cash Flow vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Investing Cash Flow figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.